{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:42:35Z","timestamp":1790523755731,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,6,6]],"date-time":"2014-06-06T00:00:00Z","timestamp":1402012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,6,6]],"date-time":"2014-06-06T00:00:00Z","timestamp":1402012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1038\/leu.2014.185","type":"journal-article","created":{"date-parts":[[2014,6,6]],"date-time":"2014-06-06T06:57:09Z","timestamp":1402037829000},"page":"406-414","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice"],"prefix":"10.1038","volume":"29","author":[{"given":"P","family":"Macor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Secco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Mezzaroba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Zorzet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Durigutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Gaiotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"De Maso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Biffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Garrovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Capolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Tripodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Gattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Marzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Tedesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Sblattero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,6]]},"reference":[{"key":"BFleu2014185_CR1","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/nbt0905-1065","volume":"23","author":"M Baker","year":"2005","unstructured":"Baker M . Upping the ante on antibodies. Nat Biotechnol 2005; 23: 1065\u20131072.","journal-title":"Nat Biotechnol"},{"key":"BFleu2014185_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.4161\/mabs.1.1.7246","volume":"1","author":"J Cohen","year":"2009","unstructured":"Cohen J, Wilson A . New challenges to medicare beneficiary access to mAbs. MAbs 2009; 1: 56\u201366.","journal-title":"MAbs"},{"key":"BFleu2014185_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/468018a","volume":"468","author":"H Ledford","year":"2010","unstructured":"Ledford H . 'Biosimilar' drugs poised to penetrate market. Nature 2010; 468: 18\u201319.","journal-title":"Nature"},{"key":"BFleu2014185_CR4","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/nbt1137","volume":"23","author":"GP Adams","year":"2005","unstructured":"Adams GP, Weiner LM . Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23: 1147\u20131157.","journal-title":"Nat Biotechnol"},{"key":"BFleu2014185_CR5","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.1158\/0008-5472.CAN-12-0063","volume":"72","author":"CW Hong","year":"2012","unstructured":"Hong CW, Zeng Q . Awaiting a new era of cancer immunotherapy. Cancer Res 2012; 72: 3715\u20133719.","journal-title":"Cancer Res"},{"key":"BFleu2014185_CR6","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1182\/blood.V99.3.1038","volume":"99","author":"JC Byrd","year":"2002","unstructured":"Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002; 99: 1038\u20131043.","journal-title":"Blood"},{"key":"BFleu2014185_CR7","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1200\/JCO.2003.06.012","volume":"21","author":"R Bannerji","year":"2003","unstructured":"Bannerji R, Kitada S, Flinn IW, Pearson M, Young D, Reed JC et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol 2003; 21: 1466\u20131471.","journal-title":"J Clin Oncol"},{"key":"BFleu2014185_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4161\/onci.1.1.17963","volume":"1","author":"P Hubert","year":"2012","unstructured":"Hubert P, Amigorena S . Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy. Oncoimmunology 2012; 1: 103\u2013105.","journal-title":"Oncoimmunology"},{"key":"BFleu2014185_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.immuni.2005.11.010","volume":"24","author":"F Nimmerjahn","year":"2006","unstructured":"Nimmerjahn F, Ravetch JV . Fcgamma receptors: old friends and new family members. Immunity 2006; 24: 19\u201328.","journal-title":"Immunity"},{"key":"BFleu2014185_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nri2744","volume":"10","author":"LM Weiner","year":"2010","unstructured":"Weiner LM, Surana R, Wang S . Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10: 317\u2013327.","journal-title":"Nat Rev Immunol"},{"key":"BFleu2014185_CR11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2741\/3688","volume":"16","author":"M Winiarska","year":"2011","unstructured":"Winiarska M, Glodkowska-Mrowka E, Bil J, Golab J . Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci (Landmark Ed) 2011; 16: 277\u2013306.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"BFleu2014185_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/cr.2009.139","volume":"20","author":"JR Dunkelberger","year":"2010","unstructured":"Dunkelberger JR, Song WC . Complement and its role in innate and adaptive immune responses. Cell Res 2010; 20: 34\u201350.","journal-title":"Cell Res"},{"key":"BFleu2014185_CR13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nri2620","volume":"9","author":"PF Zipfel","year":"2009","unstructured":"Zipfel PF, Skerka C . Complement regulators and inhibitory proteins. Nat Rev Immunol 2009; 9: 729\u2013740.","journal-title":"Nat Rev Immunol"},{"key":"BFleu2014185_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.imlet.2007.04.014","volume":"111","author":"P Macor","year":"2007","unstructured":"Macor P, Tedesco F . Complement as effector system in cancer immunotherapy. Immunol Lett 2007; 111: 6\u201313.","journal-title":"Immunol Lett"},{"key":"BFleu2014185_CR15","doi-asserted-by":"publisher","first-page":"5613","DOI":"10.1158\/0008-5472.CAN-13-1852","volume":"73","author":"J Maher","year":"2013","unstructured":"Maher J, Adami AA . Antitumor immunity: easy as 1, 2, 3 with monoclonal bispecific trifunctional antibodies? Cancer Res 2013; 73: 5613\u20135617.","journal-title":"Cancer Res"},{"key":"BFleu2014185_CR16","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","volume":"69","author":"PA Baeuerle","year":"2009","unstructured":"Baeuerle PA, Reinhardt C . Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009; 69: 4941\u20134944.","journal-title":"Cancer Res"},{"key":"BFleu2014185_CR17","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1097\/CJI.0b013e318156750c","volume":"30","author":"K Brischwein","year":"2007","unstructured":"Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother 2007; 30: 798\u2013807.","journal-title":"J Immunother"},{"key":"BFleu2014185_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.imbio.2008.11.014","volume":"214","author":"C Haas","year":"2009","unstructured":"Haas C, Krinner E, Brischwein K, Hoffmann P, Lutterbuse R, Schlereth B et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 2009; 214: 441\u2013453.","journal-title":"Immunobiology"},{"key":"BFleu2014185_CR19","first-page":"22","volume":"11","author":"PA Baeuerle","year":"2009","unstructured":"Baeuerle PA, Kufer P, Bargou R . BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 2009; 11: 22\u201330.","journal-title":"Curr Opin Mol Ther"},{"key":"BFleu2014185_CR20","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","volume":"119","author":"M Klinger","year":"2012","unstructured":"Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab. Blood 2012; 119: 6226\u20136233.","journal-title":"Blood"},{"key":"BFleu2014185_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/ncb1824","volume":"11","author":"D Maetzel","year":"2009","unstructured":"Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009; 11: 162\u2013171.","journal-title":"Nat Cell Biol"},{"key":"BFleu2014185_CR22","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.4049\/jimmunol.160.7.3437","volume":"160","author":"VT Blok","year":"1998","unstructured":"Blok VT, Daha MR, Tijsma O, Harris CL, Morgan BP, Fleuren GJ et al. A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement. J Immunol 1998; 160: 3437\u20133443.","journal-title":"J Immunol"},{"key":"BFleu2014185_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/labinvest.3780441","volume":"82","author":"KA Gelderman","year":"2002","unstructured":"Gelderman KA, Blok VT, Fleuren GJ, Gorter A . The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. Lab Invest 2002; 82: 483\u2013493.","journal-title":"Lab Invest"},{"key":"BFleu2014185_CR24","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/j.1749-6632.2009.04803.x","volume":"1173","author":"A Klepfish","year":"2009","unstructured":"Klepfish A, Gilles L, Ioannis K, Rachmilewitz EA, Schattner A . Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement\/rituximab interactions & clinical results in refractory CLL. Ann NY Acad Sci 2009; 1173: 865\u2013873.","journal-title":"Ann NY Acad Sci"},{"key":"BFleu2014185_CR25","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1093\/qjmed\/hcn085","volume":"101","author":"A Klepfish","year":"2008","unstructured":"Klepfish A, Rachmilewitz EA, Kotsianidis I, Patchenko P, Schattner A . Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL. QJM 2008; 101: 737\u2013740.","journal-title":"QJM"},{"key":"BFleu2014185_CR26","doi-asserted-by":"crossref","unstructured":"Tedesco F, Bulla B, Fischetti F . Terminal complement complex: regulation of formation and pathophysiological function. In: Szebeni J ed The Complement System: Novel Rules in Health and Disease, pp 97\u2013127 2004.","DOI":"10.1007\/1-4020-8056-5_6"},{"key":"BFleu2014185_CR27","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/j.1365-3083.1990.tb03196.x","volume":"32","author":"P Garred","year":"1990","unstructured":"Garred P, Hetland G, Mollnes TE, Stoervold G . Synthesis of C3, C5, C6, C7, C8, and C9 by human fibroblasts. Scand J Immunol 1990; 32: 555\u2013560.","journal-title":"Scand J Immunol"},{"key":"BFleu2014185_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1046\/j.1365-2249.2000.01238.x","volume":"121","author":"H Langeggen","year":"2000","unstructured":"Langeggen H, Pausa M, Johnson E, Casarsa C, Tedesco F . The endothelium is an extrahepatic site of synthesis of the seventh component of the complement system. Clin Exp Immunol 2000; 121: 69\u201376.","journal-title":"Clin Exp Immunol"},{"key":"BFleu2014185_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1600-0463.2001.tb00016.x","volume":"109","author":"H Langeggen","year":"2001","unstructured":"Langeggen H, Berge KE, Macor P, Fischetti F, Tedesco F, Hetland G et al. Detection of mRNA for the terminal complement components C5, C6, C8 and C9 in human umbilical vein endothelial cells in vitro. APMIS 2001; 109: 73\u201378.","journal-title":"APMIS"},{"key":"BFleu2014185_CR30","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.it.2004.01.008","volume":"25","author":"KA Gelderman","year":"2004","unstructured":"Gelderman KA, Tomlinson S, Ross GD, Gorter A . Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 2004; 25: 158\u2013164.","journal-title":"Trends Immunol"},{"key":"BFleu2014185_CR31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0161-5890(03)00112-3","volume":"40","author":"Z Fishelson","year":"2003","unstructured":"Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M . Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003; 40: 109\u2013123.","journal-title":"Mol Immunol"},{"key":"BFleu2014185_CR32","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/eji.200425920","volume":"35","author":"F Ziller","year":"2005","unstructured":"Ziller F, Macor P, Bulla R, Sblattero D, Marzari R, Tedesco F . Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur J Immunol 2005; 35: 2175\u20132183.","journal-title":"Eur J Immunol"},{"key":"BFleu2014185_CR33","doi-asserted-by":"publisher","first-page":"10556","DOI":"10.1158\/0008-5472.CAN-07-1811","volume":"67","author":"P Macor","year":"2007","unstructured":"Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, Marzari R et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 2007; 67: 10556\u201310563.","journal-title":"Cancer Res"},{"key":"BFleu2014185_CR34","first-page":"1002","volume":"88","author":"J Golay","year":"2003","unstructured":"Golay J, Manganini M, Facchinetti V, Gramigna R, Broady R, Borleri G et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 2003; 88: 1002\u20131012.","journal-title":"Haematologica"},{"key":"BFleu2014185_CR35","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900.012k14_3900_3908","volume":"95","author":"J Golay","year":"2000","unstructured":"Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900\u20133908.","journal-title":"Blood"},{"key":"BFleu2014185_CR36","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.4049\/jimmunol.171.3.1581","volume":"171","author":"N Di Gaetano","year":"2003","unstructured":"Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003; 171: 1581\u20131587.","journal-title":"J Immunol"},{"key":"BFleu2014185_CR37","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1472-6750-7-46","volume":"7","author":"R Di Niro","year":"2007","unstructured":"Di Niro R, Ziller F, Florian F, Crovella S, Stebel M, Bestagno M et al. Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models. BMC Biotechnol 2007; 7: 46.","journal-title":"BMC Biotechnol"},{"key":"BFleu2014185_CR38","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nbt1087","volume":"23","author":"J Fang","year":"2005","unstructured":"Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 2005; 23: 584\u2013590.","journal-title":"Nat Biotechnol"},{"issue":"Pt 3","key":"BFleu2014185_CR39","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1099\/0022-1317-73-3-653","volume":"73","author":"T Hanke","year":"1992","unstructured":"Hanke T, Szawlowski P, Randall RE . Construction of solid matrix-antibody-antigen complexes containing simian immunodeficiency virus p27 using tag-specific monoclonal antibody and tag-linked antigen. J Gen Virol 1992; 73 (Pt 3): 653\u2013660.","journal-title":"J Gen Virol"},{"key":"BFleu2014185_CR40","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.nbt.2011.12.005","volume":"29","author":"S Boscolo","year":"2012","unstructured":"Boscolo S, Mion F, Licciulli M, Macor P, De Maso L, Brce M et al. Simple scale-up of recombinant antibody production using an UCOE containing vector. N Biotechnol 2012; 29: 477\u2013484.","journal-title":"N Biotechnol"},{"key":"BFleu2014185_CR41","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1158\/0008-5472.CAN-05-3434","volume":"66","author":"P Macor","year":"2006","unstructured":"Macor P, Mezzanzanica D, Cossetti C, Alberti P, Figini M, Canevari S et al. Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. Cancer Res 2006; 66: 3876\u20133883.","journal-title":"Cancer Res"},{"key":"BFleu2014185_CR42","doi-asserted-by":"publisher","first-page":"e74216","DOI":"10.1371\/journal.pone.0074216","volume":"8","author":"N Mezzaroba","year":"2013","unstructured":"Mezzaroba N, Zorzet S, Secco E, Biffi S, Tripodo C, Calvaruso M et al. New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil\/hydroxychloroquine-loaded anti-CD20 nanoparticles. PLoS One 2013; 8: e74216.","journal-title":"PLoS One"},{"key":"BFleu2014185_CR43","doi-asserted-by":"publisher","first-page":"272","DOI":"10.2310\/7290.2008.00028","volume":"7","author":"S Biffi","year":"2008","unstructured":"Biffi S, Garrovo C, Macor P, Tripodo C, Zorzet S, Secco E et al. In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. Mol Imaging 2008; 7: 272\u2013282.","journal-title":"Mol Imaging"},{"key":"BFleu2014185_CR44","doi-asserted-by":"publisher","first-page":"e57150","DOI":"10.1371\/journal.pone.0057150","volume":"8","author":"S Biffi","year":"2013","unstructured":"Biffi S, Dal Monego S, Dullin C, Garrovo C, Bosnjak B, Licha K et al. Dendritic polyglycerolsulfate near infrared fluorescent (NIRF) dye conjugate for non-invasively monitoring of inflammation in an allergic asthma mouse model. PLoS One 2013; 8: e57150.","journal-title":"PLoS One"},{"key":"BFleu2014185_CR45","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/protein\/9.7.617","volume":"9","author":"JB Ridgway","year":"1996","unstructured":"Ridgway JB, Presta LG, Carter P . 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9: 617\u2013621.","journal-title":"Protein Eng"},{"key":"BFleu2014185_CR46","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.pep.2007.03.007","volume":"54","author":"CD Reed","year":"2007","unstructured":"Reed CD, Rast H, Hu WG, Mah D, Nagata L, Masri SA . Expression of furin-linked Fab fragments against anthrax toxin in a single mammalian expression vector. Protein Expr Purif 2007; 54: 261\u2013266.","journal-title":"Protein Expr Purif"},{"key":"BFleu2014185_CR47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/00002371-199603000-00002","volume":"19","author":"S Funakoshi","year":"1996","unstructured":"Funakoshi S, Longo DL, Murphy WJ . Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas. J Immunother Emphasis Tumor Immunol 1996; 19: 93\u2013101.","journal-title":"J Immunother Emphasis Tumor Immunol"},{"key":"BFleu2014185_CR48","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1182\/blood-2002-06-1761","volume":"101","author":"MS Cragg","year":"2003","unstructured":"Cragg MS, Morgan SM, Chan HT, Morgan BP, Filatov AV, Johnson PW et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003; 101: 1045\u20131052.","journal-title":"Blood"},{"key":"BFleu2014185_CR49","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1182\/blood-2003-06-2031","volume":"103","author":"MS Cragg","year":"2004","unstructured":"Cragg MS, Glennie MJ . Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004; 103: 2738\u20132743.","journal-title":"Blood"},{"key":"BFleu2014185_CR50","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.4049\/jimmunol.1200846","volume":"189","author":"L Gunn","year":"2012","unstructured":"Gunn L, Ding C, Liu M, Ma Y, Qi C, Cai Y et al. Opposing roles for complement component C5a in tumor progression and the tumor microenvironment. J Immunol 2012; 189: 2985\u20132994.","journal-title":"J Immunol"},{"key":"BFleu2014185_CR51","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1182\/blood.V99.1.185","volume":"99","author":"A Dobrina","year":"2002","unstructured":"Dobrina A, Pausa M, Fischetti F, Bulla R, Vecile E, Ferrero E et al. Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo. Blood 2002; 99: 185\u2013192.","journal-title":"Blood"},{"key":"BFleu2014185_CR52","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/ni.1655","volume":"9","author":"MM Markiewski","year":"2008","unstructured":"Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C et al. Modulation of the antitumor immune response by complement. Nat Immunol 2008; 9: 1225\u20131235.","journal-title":"Nat Immunol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2014185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2014185","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2014185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:33:18Z","timestamp":1689294798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2014185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,6]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["BFleu2014185"],"URL":"https:\/\/doi.org\/10.1038\/leu.2014.185","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,6]]},"assertion":[{"value":"21 February 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}